EL7.AI 上提供的信息仅供教育和参考目的，不构成财务建议。
On March 17, the National Comprehensive Cancer Network (NCCN) updated its 2026 Clinical Practice Guidelines to include ANKTIVA in combination with BCG, targeting patients with BCG-unresponsive non-muscle invasive bladder cancer. ImmunityBio, a commercial-stage immunotherapy company listed on NASDAQ, is behind this treatment. However, on March 24, ImmunityBio's shares fell 20% after the U.S. Food and Drug Administration issued a warning letter stating that a television advertisement and podcast promoting its cancer therapy were false or misleading and violated federal law.